Phaseline

Companies › aTyr Pharma

aTyr Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
efzofitimod
TREM2 agonist
TREM2Phase 2Interstitial Lung Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05892614efzofitimodPhase 2Interstitial Lung DiseaseRespiratoryApr 2026

From the company's SEC filings

Cash and short-term investments of $49m on 2026-09-30; operating cash outflow about $42m a year; runway about 14 months at that burn, to Nov 2027

Press releases filed as 8-K in the last year:

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

TREM2 (1)

Companies with the same targets

–

Companies built like this

Rein Therapeutics Expedition Therapeutics Dragonboat Biopharmaceutical Company Kinaset Therapeutics Melius Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.